India's Weight-Loss Drug Market to Expand Following Semaglutide Patent Expiry

India's weight-loss drug market is expected to grow fivefold to Rs 5,000 crore by 2030, driven by the expiry of Novo Nordisk's semaglutide patent on March 20. Several Indian pharmaceutical companies, including Mankind Pharma and Sun Pharma, plan to launch generic versions at about half the current price. This is anticipated to increase drug accessibility and obesity treatment demand, though challenges like patent litigations and manufacturing complexities remain for generics.